Sang-Hun Jung

List of Publications by Year
in descending order

117 papers	3,529 citations	172386 29 h-index	161767 54 g-index
118 all docs	118 docs citations	118 times ranked	5171 citing authors

#	Article	IF	Citations
1	An Overview of Severe Acute Respiratory Syndromeâ€“Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry, 2016, 59, 6595-6628.	2.9	602
2	Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-ÎºB without affecting IÎºB degradation. FEBS Letters, 2004, 571, 50-54.	1.3	206
3	Inhibitors of Melanogenesis: An Updated Review. Journal of Medicinal Chemistry, 2018, 61, 7395-7418.	2.9	200
4	Synthesis and Evaluation of Homoaza Sugars as Glycosidase Inhibitors. Journal of Organic Chemistry, 1995, 60, 1492-1501.	1.7	156
5	Recent development of signaling pathways inhibitors of melanogenesis. Cellular Signalling, 2017, 40, 99-115.	1.7	147
6	Downregulation of melanogenesis: drug discovery and therapeutic options. Drug Discovery Today, 2017, 22, 282-298.	3.2	115
7	An Efficient Multigram-Scale Preparation of Dihydroxyacetone Phosphate. Journal of Organic Chemistry, 1994, 59, 7182-7184.	1.7	72
8	Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1254-1258.	1.0	64
9	Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2991-2993.	1.0	58
10	Inhibitors of melanogenesis: a patent review (2009 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 775-788.	2.4	56
11	Benzoxathiole Derivative Blocks Lipopolysaccharide-Induced Nuclear Factor-ÎºB Activation and Nuclear Factor-ÎºB-Regulated Gene Transcription through Inactivating Inhibitory ÎºB Kinase Î². Molecular Pharmacology, 2008, 73, 1309-1318.	1.0	55
12	A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochemical Pharmacology, 2002, 64, 473-480.	2.0	54
13	Structural requirement of chalcones for the inhibitory activity of interleukin-5. Bioorganic and Medicinal Chemistry, 2007, 15, 104-111.	1.4	53
14	Structural requirement of isoflavonones for the inhibitory activity of interleukin-5. European Journal of Medicinal Chemistry, 2003, 38, 537-545.	2.6	52
15	MD-2 as the Target of Nonlipid Chalcone in the Inhibition of Endotoxin LPS-Induced TLR4 Activity. Journal of Infectious Diseases, 2011, 203, 1012-1020.	1.9	52
16	Synthesis and melanin biosynthesis inhibitory activity of (Â±)-terrein produced by Penicillium sp. 20135. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 471-473.	1.0	44
17	Terpenoids and Coumarins Isolated from the Fruits of Poncirus trifoliata. Chemical and Pharmaceutical Bulletin, 2008, 56, 839-842.	0.6	41
18	Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 950-954.	1.0	41

#	Article	IF	Citations
19	IRAK4 as a Molecular Target in the Amelioration of Innate Immunityâ€“Related Endotoxic Shock and Acute Liver Injury by Chlorogenic Acid. Journal of Immunology, 2015, 194, 1122-1130.	0.4	40
20	Enantioselective stabilization of inclusion complexes of metoprolol in carboxymethylated Î²-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis, 2002, 27, 569-576.	1.4	37
21	Refinement of the pharmacophore of 3,4-dihydroquinazoline-2(1H)-thiones for their anti-melanogenesis activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4771-4773.	1.0	35
22	Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis. Bioorganic and Medicinal Chemistry, 2010, 18, 1135-1142.	1.4	34
23	Evaluation of 3,4-dihydroquinazoline-2(1H)-thiones as inhibitors of Î±-MSH-induced melanin production in melanoma B16 cells. Bioorganic and Medicinal Chemistry, 2010, 18, 1555-1562.	1.4	34
24	Enhanced transdermal drug delivery of zaltoprofen using a novel formulation. International Journal of Pharmaceutics, 2013, 453, 358-362.	2.6	34
25	Synthesis and SAR studies of bis-chromenone derivatives for anti-proliferative activity against human cancer cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5256-5259.	1.0	34
26	Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2553-2558.	1.0	33
27	Structural characteristics of thiosemicarbazones as inhibitors of melanogenesis. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6794-6796.	1.0	33
28	Highly efficient synthesis of alkylidene- and allylidenecyclopropanes. Tetrahedron Letters, 1988, 29, 25-26.	0.7	32
29	Synthesis and evaluation of novel chromone analogs for their inhibitory activity against interleukin-5. European Journal of Medicinal Chemistry, 2010, 45, 2531-2536.	2.6	31
30	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1Î± inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6305-6310.	1.0	29
31	Structural requirement of phenylthiourea analogs for their inhibitory activity of melanogenesis and tyrosinase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6824-6828.	1.0	29
32	cAMP-Binding Site of PKA as a Molecular Target of Bisabolangelone against Melanocyte-Specific Hyperpigmented Disorder. Journal of Investigative Dermatology, 2013, 133, 1072-1079.	0.3	29
33	Melanogenesis inhibitory daphnane diterpenoids from the flower buds of Daphne genkwa. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3334-3337.	1.0	27
34	Synthesis and evaluation of cytotoxicity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Archives of Pharmacal Research, 1996, 19, 570-580.	2.7	26
35	Investigation of amino acid conjugates of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282) as water soluble anticancer prodrugs. European Journal of Medicinal Chemistry, 2014, 80, 439-446.	2.6	26
36	Novel diarylsulfonylurea derivatives as potent antimitotic agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6075-6078.	1.0	25

#	Article	IF	Citations
37	Manassantin A inhibits cAMPâ€induced melanin production by downâ€regulating the gene expressions of MITF and tyrosinase in melanocytes. Experimental Dermatology, 2011, 20, 761-763.	1.4	25
38	Suppressive effect of novel aromatic diamine compound on nuclear factor-ÎºB-dependent expression of inducible nitric oxide synthase in macrophages. European Journal of Pharmacology, 2005, 521, 1-8.	1.7	24
39	Ketonethiosemicarbazones: Structureâ€“activity relationships for their melanogenesis inhibition. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3527-3530.	1.0	24
40	Effect of substituents on benzenesulfonyl motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicity. Archives of Pharmacal Research, 2000, 23, 579-584.	2.7	23
41	Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-ÎºB. Bioorganic and Medicinal Chemistry, 2016, 24, 1872-1878.	1.4	23
42	The 3D-QSAR study of antitumor arylsulfonylimidazolidinone derivatives by CoMFA and CoMSIA. Bioorganic and Medicinal Chemistry, 2003, 11, 4585-4589.	1.4	22
43	A new reductive procedure for the preparation of vicinal diamines and monoamines. Tetrahedron Letters, 1984, 25, 399-402.	0.7	21
44	Recognition of pharmacophore of ar-turmerone for its anticancer activity. Archives of Pharmacal Research, 1993, 16, 254-256.	2.7	21
45	Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1547-1550.	1.0	21
46	Recognition of the importance of imidazolidinone motif for cytotoxicity of 4-phenyl-1-arylsulfonylimidazolidinones using thiadiazolidine-1,1 -dioxide analogs. Archives of Pharmacal Research, 2002, 25, 421-427.	2.7	21
47	Identification of novel chromenone derivatives as interleukin-5 inhibitors. European Journal of Medicinal Chemistry, 2013, 59, 31-38.	2.6	21
48	Planar structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-imidazolones for their cytotoxicity. Archives of Pharmacal Research, 1997, 20, 283-287.	2.7	20
49	Enantioselective preparation of metoprolol and its major metabolites. Archives of Pharmacal Research, 2000, 23, 226-229.	2.7	20
50	Importance of sulfonylimidazolidinone motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicity: Synthesis of 2-benzoyl-4-phenyl[1,2,5]thiazolidine-1,1-dioxides and their cytotoxcity. Archives of Pharmacal Research, 2003, 26, 9-14.	2.7	20
51	<scp>cAMP</scp>â€dependent activation of protein kinase <scp>A</scp> as a therapeutic target of skin hyperpigmentation by diphenylmethylene hydrazinecarbothioamide. British Journal of Pharmacology, 2015, 172, 3434-3445.	2.7	20
52	Investigation of chemical reactivity of 2-alkoxy-1,4-naphthoquinones and their anticancer activity. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2023-2028.	1.0	20
53	Antitumor activity of 4-phenyl-1-arylsulfonylimidazolidinone, DW2143. Cancer Letters, 1999, 140, 177-187.	3.2	18
54	Exploration of essential structure of malloapelta B for the inhibitory activity against TNF induced NF-ÎºB activation. Archives of Pharmacal Research, 2006, 29, 840-844.	2.7	17

#	Article	IF	Citations
55	Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorganic and Medicinal Chemistry, 2010, 18, 4625-4629.	1.4	16
56	Structureâ€“activity relationship of naphthaldehydethiosemicarbazones in melanogenesis inhibition. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 886-889.	1.0	16
57	Evaluation of the role of imidazolidinone motif of antineoplas-tic 4-phenyl-1-arylsulfonylimidazolidinones using 4-phenyl-2-aryl-sulfonyloxazolines. Archives of Pharmacal Research, 2001, 24, 499-502.	2.7	15
58	JNK-mediated transcriptional upregulation of RhoB is critical for apoptosis of HCT-116 colon cancer cells by a novel diarylsulfonylurea derivative. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1540-1548.	2.2	15
59	The role of Alkoxy group on the a ring of isoflavones in the inhibition of Interleukin-5. Archives of Pharmacal Research, 2007, 30, 950-954.	2.7	14
60	Hypopigmenting Activity of Bisabolangelone Isolated fromAngelica koreanaMaxim. inÎ±-Melanocyte Stimulating Hormone-Activated B16 or Melan-a Cells. Planta Medica, 2011, 77, 248-251.	0.7	14
61	Melanogenesis inhibitory bisabolane-type sesquiterpenoids from the roots of Angelica koreana. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2927-2931.	1.0	14
62	Downregulation of Melanocyte-Specific Facultative Melanogenesis by 4-Hydroxy-3-Methoxycinnamaldehyde Acting as a cAMP Antagonist. Journal of Investigative Dermatology, 2014, 134, 551-553.	0.3	14
63	Synthesis and anti-proliferative activity of novel azazerumbone conjugates with chalcones. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5182-5185.	1.0	14
64	The role of the hydrophobic group on ring A of chalcones in the inhibition of interleukin-5. Archives of Pharmacal Research, 2006, 29, 969-976.	2.7	13
65	Identification of Indoline-2-thione Analogs as Novel Potent Inhibitors of .ALPHA.-Melanocyte Stimulating Hormone Induced Melanogenesis. Chemical and Pharmaceutical Bulletin, 2011, 59, 1285-1288.	0.6	13
66	Novel interleukin-5 inhibitors based on hydroxyethylaminomethyl-4H-chromen-4-one scaffold. Bioorganic and Medicinal Chemistry, 2012, 20, 5757-5762.	1.4	13
67	Anti-proliferative effect of chalcone derivatives through inactivation of NF-ÎºB in human cancer cells. Bioorganic and Medicinal Chemistry, 2014, 22, 3386-3392.	1.4	13
68	Stereochemical requirement at 4-position of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicities. Archives of Pharmacal Research, 2000, 23, 35-41.	2.7	12
69	Preparation and evaluation of solid lipid nanoparticles with JSH18 for skin-whitening efficacy. Pharmaceutical Development and Technology, 2010, 15, 415-420.	1.1	12
70	Study on anti-proliferative effect of benzoxathiole derivatives through inactivation of NF-ÎºB in human cancer cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4523-4527.	1.0	12
71	Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase. European Journal of Medicinal Chemistry, 2016, 117, 113-124.	2.6	12
72	Evaluation of anticancer activity of 4-vinyl-1-arylsulfonylimidazolidinones. Archives of Pharmacal Research, 2006, 29, 721-727.	2.7	11

#	Article	IF	Citations
73	Design and synthesis of novel chromenone derivatives as interleukin-5 inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 2543-2550.	1.4	11
74	Preformulation and formulation of newly synthesized QNT3-18 for development of a skin whitening agent. Drug Development and Industrial Pharmacy, 2013, 39, 526-533.	0.9	11
75	Synthesis and cytotoxic activity of 1-(1-benzoylindoline-5-sulfonyl)-4-phenylimidazolidinones. Archives of Pharmacal Research, 2004, 27, 478-484.	2.7	10
76	The scope of thallium nitrate oxidative cyclization of chalcones; synthesis and evaluation of isoflavone and aurone analogs for their inhibitory activity against interleukin-5. Bioorganic and Medicinal Chemistry, 2010, 18, 4441-4445.	1.4	10
77	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator. European Journal of Medicinal Chemistry, 2018, 143, 1869-1887.	2.6	10
78	Structureâ€“activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity. European Journal of Medicinal Chemistry, 2011, 46, 3258-3264.	2.6	9
79	A SAR study on a series of synthetic lipophilic chalcones as Inhibitor of transcription factor NF-ÎºB. European Journal of Medicinal Chemistry, 2012, 54, 379-386.	2.6	9
80	Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. ACS Medicinal Chemistry Letters, 2015, 6, 758-763.	1.3	9
81	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure. European Journal of Medicinal Chemistry, 2017, 134, 379-391.	2.6	9
82	The role of substituents ofar-turmerone for its anticancer activity. Archives of Pharmacal Research, 1992, 15, 256-262.	2.7	8
83	Anti-inflammatory Benzene Diamine Compound Inhibited Toll-Like Receptor 4-Mediated Inducible Nitric Oxide Synthase Expression and Nuclear Factor-KappaB Activation. Biological and Pharmaceutical Bulletin, 2005, 28, 908-911.	0.6	8
84	Facile Synthesis of Trisaccharide Moiety Corresponding to Antitumor Activity in Triterpenoid Saponins Isolated from Pullsatilla Roots. Chemical and Pharmaceutical Bulletin, 2007, 55, 1734-1739.	0.6	8
85	A convenient preparation of a disaccharide motif and its role in the cytotoxicity of the triterpenoid saponin, Î±-hederin. Archives of Pharmacal Research, 2008, 31, 555-561.	2.7	8
86	Physicochemical studies of a newly synthesized molecule, 6-methyl-3-phenethyl-3,4-dihydro-1H-quinazoline-2-thione (JSH18) for topical formulations. Archives of Pharmacal Research, 2008, 31, 1363-1368.	2.7	8
87	Structural requirements of (E)-6-benzylidene-4a-methyl-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one derivatives as novel melanogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1922-1925.	1.0	8
88	Exploration of SAR for novel 2-benzylbenzimidazole analogs as inhibitor of transcription factor NF-ÎºB. Archives of Pharmacal Research, 2017, 40, 469-479.	2.7	8
89	Promotion of hair growth by newly synthesized ceramide mimetic compound. Biochemical and Biophysical Research Communications, 2017, 491, 173-177.	1.0	8
90	Melanogenesis inhibitory pregnane glycosides from Cynanchum atratum. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1252-1256.	1.0	8

#	Article	IF	Citations
91	Effect of DW2282 on the induction of methemoglobinemia, hypoglycemia or WBC count and hematological changes. Archives of Pharmacal Research, 1999, 22, 565-570.	2.7	7
92	Novel Benzo[d]imidazole-2(3H)-thiones as Potent Inhibitors of the .ALPHA.-Melanocyte Stimulating Hormone Induced Melanogenesis in Melanoma B16 Cells. Chemical and Pharmaceutical Bulletin, 2010, 58, 918-921.	0.6	7
93	Structureâ€“activity relationship study of arylsulfonylimidazolidinones as anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6829-6832.	1.0	7
94	Differential anti-inflammatory and analgesic effects by enantiomers of zaltoprofen in rodents. International Immunopharmacology, 2013, 16, 457-460.	1.7	7
95	Total synthesis and absolute stereochemistry of (9R,10S)-epoxyheptadecan-4,6-diyn-3-one, a diacylglycerol acyltransferase inhibitor from Panax ginseng. Tetrahedron Letters, 2004, 45, 7077-7079.	0.7	6
96	Discovery of novel 3-(hydroxyalkoxy)-2-alkylchromen-4-one analogs as interleukin-5 inhibitors. European Journal of Medicinal Chemistry, 2017, 139, 290-304.	2.6	6
97	A thorough analysis of the effect of surfactant/s on the solubility and pharmacokinetics of (S)-zaltoprofen. Asian Journal of Pharmaceutical Sciences, 2019, 14, 435-444.	4.3	6
98	Anti-inflammatory effects of N1-Benzyl-4-methylbenzene-1,2-diamine (JSH-21) analogs on nitric oxide production and nuclear factor-kappa B transcriptional activity in lipopolysaccharide-stimulated macrophages RAW 264.7. Archives of Pharmacal Research, 2004, 27, 1053-1059.	2.7	5
99	Exploration of benzamidochromenone derivatives with conformational restrictor as interleukin-5 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 2498-2504.	1.4	5
100	Exploration and Optimization of an Efficient Oneâ€pot Sequential Synthesis of Di/triâ€substituted Thiazoles from Î±â€Bromoketones, Thioacids Salt, and Ammonium Acetate. Journal of Heterocyclic Chemistry, 2016, 53, 1449-1456.	1.4	5
101	Multicentre hydrogen bonds in a 2:1 arylsulfonylimidazolone hydrochloride salt. Acta Crystallographica Section C: Crystal Structure Communications, 2000, 56, 1247-1250.	0.4	4
102	Effect of the isosteric replacement of the phenyl motif with furyl (or thienyl) of 4-phenyl-N-arylsulfonylimidazolones as broad and potent anticancer agents. MedChemComm, 2011, 2, 731.	3.5	4
103	Investigation of Nâ€Arylsulfonylimidazole as Novel Scaffold for Anticancer Agents. Bulletin of the Korean Chemical Society, 2016, 37, 632-637.	1.0	4
104	Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 65-75.	2.6	4
105	Importance of Imidazolidinone Motif in 4-Phenyl-N-arylsulfonylimidazolidinone for their Anticancer Activity. Bulletin of the Korean Chemical Society, 2011, 32, 3009-3016.	1.0	4
106	Racemization of 6-methoxydihydrosanguinarine in methanol investigated by enantioselective dynamic HPLC. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 103-106.	1.4	3
107	Sequential Oneâ€Pot Synthesis of Imidazoles and <scp>2H</scp>â€Imidazolones from Î²â€Ketoamines, Acylating Agents and Ammonium Acetate. Bulletin of the Korean Chemical Society, 2016, 37, 1966-1970.	1.0	3
108	Novel analogs of N -acylhydroxyethylaminomethyl-4 H -chromen-4-one scaffold as IL-5 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4330-4338.	1.4	3

#	Article	IF	Citations
109	Identification of N-arylsulfonylpyrimidones as anticancer agents. Archives of Pharmacal Research, 2018, 41, 251-258.	2.7	3
110	Exploration of Isosteric Replacement of Imidazolidinone Motif in 4-Phenyl-1-arylsulfonylimidazolidinone with Pyrazole and Pyrazolidinone for Cytotoxicity. Bulletin of the Korean Chemical Society, 2014, 35, 2922-2928.	1.0	3
111	Structure activity relationship of ar-turmerone analogues. Archives of Pharmacal Research, 1993, 16, 219-226.	2.7	2
112	Chiral HPLC studies on chemical behavior of 6-methoxydihydrosanguinarine in alcoholic solvent system. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 479-483.	1.4	2
113	Preformulation of FK506 Prodrugs for Improving Solubility. Bulletin of the Korean Chemical Society, 2016, 37, 1313-1319.	1.0	2
114	Piperidylmethyloxychalcone improves immune-mediated acute liver failure via inhibiting TAK1 activity. Experimental and Molecular Medicine, 2017, 49, e392-e392.	3.2	2
115	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2369-2374.	1.0	2
116	Synthesis of Water Soluble Analogs of Arylsulfonylimidazolidinone (JSH-2282). Bulletin of the Korean Chemical Society, 2013, 34, 2011-2015.	1.0	2
117	Development and Validation of HPLC Assay of a New Molecule, 6-methyl-3-phenethyl-3, 4-dihydro-1H-quinazoline-2-thione from Solid Lipid Nanoparticles and its Topical Formulations. Journal of Liquid Chromatography and Related Technologies, 2009, 32, 512-525.	0.5	1